25-d-spirosta-3, 5-diene

25-D-Spirosta-3,5-Diene (Diosgenin Congener): A Comprehensive Reference

1. Identity: Names, Chemical Characterization, and Relationship to Diosgenin

1.1 Nomenclature and Chemical Identity

The compound marketed or referenced in supplements and botanical literature under the designation 25-D-spirosta-3,5-diene (also rendered as 25d-spirosta-3,5-diene or (25R)-spirosta-3,5-diene) is a steroidal sapogenin belonging to the spirostane class of natural compounds. Its molecular formula is C₂₇H₄₀O₂, and it is registered in PubChem as CID 337494 under the name (25R)-Spirosta-3,5-diene. The "25-D" notation is a legacy stereochemical descriptor indicating the 25R absolute configuration of the spiro junction.

The NIST WebBook lists among the synonyms for the closely related compound diosgenin: "25D-spirost-5-en-3β-ol" and "25D-Spirost-5-en-3beta-ol," confirming that the "25-D" prefix is used interchangeably across this chemical family in older literature. Structurally, 25-D-spirosta-3,5-diene differs from diosgenin principally in the position and number of double bonds: the diene possesses conjugated double bonds at C-3,5 rather than a single Δ5 double bond, and it lacks the C-3 hydroxyl group present in diosgenin.

Diosgenin itself — the parent hydroxylated compound — is a naturally occurring steroidal sapogenin with the molecular formula C₂₇H₄₂O₃ and the systematic name (3β,25R)-spirost-5-en-3β-ol, characterized by a spiroacetal ring system that distinguishes it as a phytosteroid derived from plant saponins. Diosgenin has a molecular weight of 414.6 g/mol and belongs to the class of steroid sapogenins. By contrast, (25R)-spirosta-3,5-diene (MW approximately 396 g/mol, C₂₇H₄₀O₂) is the dehydrated, deoxygenated derivative.

Diosgenin has been classified as an apoptosis inducer, an antiviral agent, an antineoplastic agent and a metabolite; it is also classified as a 3beta-sterol, a spiroketal, a hexacyclic triterpenoid and a sapogenin.

1.2 Relationship to Diosgenin: Artifact or Natural Constituent?

A critical finding from the peer-reviewed literature is that 25-D-spirosta-3,5-diene is not straightforwardly an independent natural product in most plants. A 1964 reinvestigation of the fenugreek sapogenin mixture led to the isolation of diosgenin, tigogenin, and gitogenin, along with a fourth product identified as 25D-spirosta-3,5-diene; no evidence was found for trigonellagenin, which had been reported previously to occur in the same fraction. Evidence presented suggests that the diene is actually an artifact derived from diosgenin and produced early during the acid hydrolysis of the natural saponins. This finding — published in the Journal of Pharmaceutical Sciences in 1964 — has important implications: the diene may form when plant material containing diosgenin glycosides is subjected to the standard acid hydrolysis used to prepare sapogenin extracts, rather than being present as a discrete entity in the intact plant. This means that the "natural" occurrence of 25-D-spirosta-3,5-diene in commercial preparations may reflect processing conditions rather than an inherent phytochemical.

1.3 Botanical Sources

The compound is documented as a constituent (or hydrolysis artifact) across multiple plant genera:

• Dioscorea nipponica (Japanese or Chinese yam): The rhizome of Dioscorea nipponica contains dioscin, gracillin, 25-D-spirosta-3,5-diene, p-hydroxybenzyl tartaric acid, amino acids, and other components. Network pharmacology analysis of Dioscorea nipponica rhizome has revealed that saponins account for approximately 40% of the drug, alongside sterols, allantoin, resins, polysaccharides, starches, amino acids, flavonoids, and a small amount of 25α-spirosta-3,5-diene.
• Trigonella foenum-graecum (Fenugreek): As documented by the 1964 Journal of Pharmaceutical Sciences study cited above, 25-D-spirosta-3,5-diene was detected in the sapogenin fraction of fenugreek seeds.
• Tribulus terrestris: The plant contains saponins, which on hydrolysis yield sapogenins — diosgenin, gitogenin, chlorogenin, ruscogenin, and 25D-spirosta-3,5-diene, among others.
• Dioscorea villosa (Wild Yam) and related species: The genus Dioscorea broadly provides the parent sapogenin pool from which the diene can be formed during processing.

There are an estimated 600 species of yam in the genus Dioscorea; many of them are wild species that flourish in damp woodlands and thickets, and not all of them contain the medicinally active part, diosgenin. Some species are grown specifically as a source of diosgenin for laboratories to use in making steroids.

1.4 Common Commercial Forms and Preparations

In practice, dietary supplements labeled with 25-D-spirosta-3,5-diene are almost universally derived from standardized extracts of Dioscorea species (principally D. villosa or D. nipponica), or from fenugreek seed extracts, in which the diene is present as a minor sapogenin alongside the predominant compound diosgenin and its glycoside dioscin. Wild yam is usually found as a liquid extract, dried herb, powder, capsule, and tablet; the liquid can also be used to make tea, and topical creams are available. Because the diene lacks the C-3 hydroxyl that is the characteristic functional group of diosgenin, its presence in finished products is typically a marker of the acid-hydrolysis processing step and is rarely quantified separately in quality control documentation.

2. Traditional and Historical Use

2.1 Native American and Early Settler Traditions

The traditional use of the botanical sources of 25-D-spirosta-3,5-diene is substantially inseparable from the broader use of Dioscorea villosa and related yam species, since the compound itself was not isolated or identified until the twentieth century.

Common names of Dioscorea villosa include wild yam, Atlantic yam, common wild yam, wild yam-root, yellow yam, colic root, and rheumatism root; some of these English common names reflect its use in Native American and other traditional medicines. Native Americans in the southeast cultivated this plant.

Since the 18th century, herbalists have been using wild yam to treat menstrual cramps and problems related to childbirth, as well as for upset stomach and coughs.

2.2 Eclectic Medical Movement (19th Century)

Wild yam was popularized by the Eclectic medical movement in the 19th century for its supposed antispasmodic properties and was therefore prescribed for biliary colic and spasm of the bowel. It was also promoted for the relief of nausea in pregnancy and for amenorrhea and dysmenorrhea. Wild yam has been used for urinary tract infections, rheumatoid arthritis, cholera, nervous excitement, and flatulence.

2.3 Traditional Russian Herbal Medicine

In traditional Russian herbal medicine, saponin extracts from the roots of various varieties of wild yam are thought to be an anticoagulant, antisclerotic, antispasmodic, cholagogue, depurative, diaphoretic, diuretic and a vasodilator.

2.4 Traditional Chinese Medicine

Dioscorea nipponica rhizome (穿山龙, chuān shān lóng) has a documented history in Traditional Chinese Medicine. Northeast Medicinal Plant Records state: "Promotes tendon relaxation and blood circulation, treats lower back and leg pain, and numbness of tendons and bones." The Hubei Chinese Herbal Medicine Records describe it as: "Used for periodontal pain. Rheumatic fever." The Shaanxi Chinese Herbal Medicine text records: "Treats cough, rheumatoid arthritis, joint pain from Kashin-Beck disease, indigestion, malaria, traumatic injuries, and abscesses and malignant sores."

2.5 Unani (Islamic) Medicine — Tribulus

Within the Unani system, Tribulus terrestris (which contains 25-D-spirosta-3,5-diene among its sapogenins) is classified with actions described as Munzij, Mulaiyin, Jali, Mudirr-e-Baul (diuretic), Mudirr-e-Haiz, Mufattit-e-Hasat; its therapeutic uses include anti-inflammatory, anabolic, spasmolytic, muscle relaxant, hypotensive, hypoglycaemic, and aphrodisiac applications.

3. Key Constituents and Active Compounds

3.1 The Spirostane Scaffold

Both diosgenin and 25-D-spirosta-3,5-diene share the spirostane carbon skeleton — a hexacyclic framework composed of four fused carbocyclic rings (A, B, C, D — the classic steroid nucleus) and two additional rings (E and F) forming the spiroacetal system. From the structural perspective, diosgenin contains a hydrophobic steroidal backbone composed of cyclohexane and cyclopentane rings linked with hydrophilic sugar molecules (when in glycoside form). The spiroacetal moiety at the F-ring of diosgenin is susceptible to ring opening under acidic conditions, which destabilizes the acetal linkages and leads to degradation of the sapogenin structure. This acid-sensitivity is directly relevant to the formation of the 3,5-diene: dehydration and isomerization of the C-3 hydroxyl group under acidic hydrolysis conditions generates the conjugated diene system.

3.2 Diosgenin as the Pharmacologically Characterized Parent

Because 25-D-spirosta-3,5-diene has itself been the subject of minimal direct pharmacological study, the scientific evidence for the biological activities of this chemical class derives overwhelmingly from diosgenin research. The two compounds share the same stereospecific hexacyclic backbone and 25R configuration, and the diene can reasonably be considered a dehydrated congener of diosgenin in the context of biological activity evaluation, although direct extrapolation requires caution. Diosgenin has shown a vast range of pharmacological activities in preclinical studies; it exhibits anticancer, cardiovascular protective, anti-diabetes, neuroprotective, immunomodulatory, estrogenic, and skin protective effects, mainly by inducing apoptosis, suppressing malignant transformation, decreasing oxidative stress, preventing inflammatory events, promoting cellular differentiation/proliferation, and regulating T-cell immune response.

3.3 Phytochemical Co-Occurrence

In plant sources where 25-D-spirosta-3,5-diene appears, it is accompanied by the following classes of compounds which may contribute synergistically to observed biological effects:

• Steroidal saponins: Dioscin, gracillin, protodioscin (glycosides of diosgenin and related sapogenins)
• Sapogenins: Diosgenin, tigogenin, gitogenin, chlorogenin, ruscogenin
• Flavonoids (in Tribulus terrestris): Rutin, quercetin, kaempferol, kaempferol-3-glucoside and rutinoside, and tribuloside have been isolated from the leaves and fruits.
• Alkaloids: The seeds contain carboline alkaloids — harmane and harmine; harmol is also reported from the herb.
• Polysaccharides, amino acids, allantoin, resins (in Dioscorea nipponica)

4. Mechanisms of Action

Note: The mechanisms described below derive from peer-reviewed research on diosgenin and the spirostane sapogenin class. Direct mechanistic data on 25-D-spirosta-3,5-diene specifically are not available in the published literature surveyed.

4.1 Apoptosis Induction

Diosgenin interferes with cell death pathways and their regulators to induce apoptosis. Multiple pathways are involved, including activation of caspase cascades, modulation of Bcl-2 family proteins, and disruption of mitochondrial membrane potential. In breast cancer cells, diosgenin was found to regulate survival of breast cancer cells via modulation of AKT, and this compound showed selective toxicity to the cancer cells without remarkably affecting the normal epithelial cells of the breast (MCF-10A).

4.2 Anti-metastatic and Anti-angiogenic Mechanisms

Diosgenin antagonizes tumor metastasis by modulating epithelial-mesenchymal transition and actin cytoskeleton to change cellular motility, suppressing degradation of the matrix barrier, and inhibiting angiogenesis.

4.3 Anti-inflammatory Mechanisms

Its anti-inflammatory activity is through inhibiting production of pro-inflammatory cytokines, enzymes, and adhesion molecules. The modulation of important molecular targets and signaling pathways such as PI3K/AKT/mTOR, JAK/STAT, NF-κB, and MAPK play a crucial role in these effects.

4.4 Antioxidant Mechanisms

Diosgenin improves antioxidant status and inhibits lipid peroxidation. In the context of diabetic neuropathy models, diosgenin attenuated the level of malondialdehyde (MDA) but increased the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx), and increased the expression of Nrf2, HO-1, and NQO1.

4.5 Estrogenic and Hormonal Pathways

Diosgenin drives cellular growth and differentiation through the estrogen receptor (ER) cascade and transcriptional factor PPARγ. However, this is a nuanced point. Diosgenin, the saponin extracted from Dioscorea villosa (wild yam), does not bind to the human estrogen or progesterone receptor in vitro and cannot be converted in the human body to progesterone. The observed estrogenic effects in experimental models appear to be receptor-independent or mediated through indirect signaling cascades.

4.6 Interaction with Glucocorticoid Receptors

The molecular mechanism of anti-trachea inflammatory effects produced by diosgenin was evaluated via interactions with glucocorticoid receptor alpha. This glucocorticoid receptor interaction may partly explain the compound's anti-inflammatory and anti-asthmatic properties observed in preclinical models.

4.7 Cholesterol and Lipid Metabolism

Diosgenin and its analogs significantly inhibit cholesterol absorption and promote its excretion and reduce hypercholesterolemia. At the molecular level, diosgenin has been shown to influence macrophage cholesterol metabolism through suppression of miR-19b-induced downregulation of ATP-binding cassette transporter A1 (ABCA1), a key regulator of reverse cholesterol transport.

4.8 Neuroprotective Pathways

Diosgenin reverses functional and structural changes and induces neural regeneration in a diabetic neuropathy model. Diosgenin treatment not only reduces amyloid plaques and neurofibrillary tangles in the brain, but also improves memory and reduces axonal degeneration by activating the membrane-associated rapid response steroid-binding receptor in a mouse Alzheimer's disease model.

4.9 Bone Metabolism

Studies indicate that diosgenin may protect against bone loss in experimental models of senescence, menopause, and retinoic acid-induced osteoporosis; the mechanism of action is still not fully clear but can be associated with a modulation of the receptor activator of NF-κB ligand (RANKL)/osteoprotegerin ratio.

5. Scientific Evidence by Area of Use

All evidence summarized below derives from research on the broader spirostane sapogenin class, principally diosgenin, given the absence of direct clinical trials on 25-D-spirosta-3,5-diene as an isolated compound. Evidence levels are characterized honestly.

5.1 Cancer Biology

Evidence level: Preclinical only (in vitro and animal); no registered human trials on isolated compound.

This bioactive phytochemical has shown high potential and interest in the treatment of various disorders such as cancer, diabetes, arthritis, asthma, and cardiovascular disease. Preclinical studies have shown promising effects on cancer, neuroprotection, atherosclerosis, asthma, bone health, and other pathologies.

Cancer-relevant activities documented in cell line and animal studies include:

• Induction of apoptosis in colon, breast, cervical, osteosarcoma, and other cancer cell lines
• Significant inhibition of cell viability and motility of breast cancer cells and stimulation of apoptosis via suppression of S-phase kinase-associated protein Skp-2.
• Antiproliferative effects against seven human cancer cell lines have been assayed for isolated spirostanol saponins; certain compounds exhibited potential antiproliferative activities against all human cancer cell lines tested.

The absence of clinical trials remains a key limitation in translating diosgenin into a viable therapeutic agent for cancer. To date, no trials have investigated its efficacy or safety in hepatocellular carcinoma patients, either as monotherapy or in combination with standard treatments.

5.2 Cardiovascular and Atherosclerosis

Evidence level: Preclinical (in vitro and animal); minimal human data.

Atherosclerosis is a disease of the middle and large arteries characterized by the formation of atheromatous plaques containing accumulations of LDL-cholesterol, which can trigger serious problems including heart failure, stroke, or death. The pathogenic mechanisms are complex, involving lipid peroxidation, oxidative stress, inflammation, or altered immune response.

Diosgenin and its analogs significantly inhibit cholesterol absorption and promote its excretion, thereby reducing hypercholesterolemia; they are also widely available and low cost, and are expected to become a new alternative anti-atherosclerosis treatment candidate.

In the human setting, the clinical application of diosgenin has found no changes in weight, systolic or diastolic blood pressure, total serum cholesterol, or triglyceride at dosages studied in clinical trials. This finding substantially limits the translation of preclinical lipid-lowering data to clinical practice.

5.3 Diabetes and Metabolic Disease

Evidence level: Preclinical (in vitro and animal); very limited human data.

In experimental models, diosgenin led to a reduction of plasma and hepatic triglycerides in obese diabetic mice and may be useful for the management of diabetes-related hepatic dyslipidemias. In diosgenin-treated diabetic rats, a reduction of hyperglycemia, hypercholesterolemia, and hypertriglyceridemia was observed, as well as improved levels of the antioxidant enzymes SOD and GPx and a minimized level of lipid peroxidation.

In a preclinical neuroprotection study, eligible mice were divided into groups receiving low-dose (50 mg/kg) and high-dose (100 mg/kg) diosgenin; the main outcome indicates that diosgenin significantly reduced the level of blood glucose and increased the body weight of diabetic mice.

5.4 Neuroprotection and Cognitive Function

Evidence level: Mostly preclinical; one cited human study on cognitive function exists but is not fully detailed in the sources retrieved.

As a natural antioxidant, diosgenin is known to have neuroprotective effects and to improve some aging-related deficits, namely, memory improvement.

Microglia-mediated neuroinflammation resulting in dopaminergic neuron loss may lead to the pathogenesis of Parkinson's disease. Lipopolysaccharide (LPS), an endotoxin, induces neuroinflammatory microglial activation, contributing to dopaminergic neuron damage. In vitro and in vivo preclinical models have been used to investigate diosgenin's capacity to prevent this neuroinflammatory cascade.

Clinical investigations have demonstrated diosgenin's promising benefits on cognitive function and menopause, though these clinical data are limited and the full methodology and results of these trials are not comprehensively reported in the reviewed literature.

Animal study results demonstrate that diosgenin can ameliorate behavioural and morphological changes in diabetic peripheral neuropathy by reducing oxidative stress; the Nrf2/HO-1 signalling pathway was involved in its neuroprotective effects.

5.5 Bone Health and Osteoporosis

Evidence level: Preclinical (animal models); no human clinical trials confirmed.

Dioscorea was found to increase bone mineral density in ovariectomised rats, but studies in humans are lacking.

In the context of postmenopausal osteoporosis in the ovariectomized rat model, diosgenin has been shown to be effective in countering bone loss related to estrogen deficiency.

5.6 Hormonal and Reproductive Health

Evidence level: Preclinical; negative human evidence for in vivo conversion to hormones.

Currently, wild yam's use as a natural hormone supplement appears to be based on the unsupported concept that it is a natural source or precursor of progesterone. Extracts of D. villosa contain steroidal saponins, diosgenin, alkaloids, tannins, phytosterols, and starch. However, evidence suggesting that diosgenin or dioscin can be converted into human hormones is lacking.

Studies disprove the conversion of diosgenin into steroids in the human body, showing that diosgenin requires chemical reactions that can only take place in a laboratory setting to convert it into steroids like progesterone, estrogen, and DHEA. As a result, scientific evidence does not currently support wild yam root's effectiveness for treating conditions associated with hormonal imbalances, such as PMS, low sex drive, infertility, and weakened bones.

When given as a cream, the effect of Dioscorea on menopausal symptoms was not statistically significant compared to placebo.

The only available clinical studies involving diosgenin have been limited to non-cancerous conditions, such as polycystic ovary syndrome (NCT06639698), menopause, and cognitive function.

5.7 Inflammatory and Autoimmune Conditions

Evidence level: Preclinical (cell culture and animal models); no controlled human trials confirmed.

Dioscorea nipponica rhizome possesses pharmacological effects such as anti-inflammatory, analgesic, cardiovascular protective, antitussive and antiasthmatic, and expectorant actions in preclinical and traditional use contexts.

The effects of diosgenin in a mouse model of Graves' disease were also investigated, and it was observed that this steroid can relieve goiter through the inhibition of thyrocyte proliferation; the mechanisms for this action involve the suppression of IGF-1, NF-κB, cyclin D1, and PCNA expression.

5.8 Anti-asthmatic Activity

Evidence level: Preclinical only.

Asthma is a long-term condition which results in inflammation of the lower respiratory tract. Junchao and coworkers evaluated the molecular mechanism of anti-trachea inflammatory effects produced by diosgenin via interactions with glucocorticoid receptor alpha, using ovalbumin-induced asthmatic mice and primary tracheal epithelial cells.

6. Industrial and Pharmaceutical Significance

6.1 The Marker Degradation and Steroid Industry

While not a therapeutic use, the industrial relevance of the spirostane sapogenin class — including the precursor chemistry linked to 25-D-spirosta-3,5-diene — is foundational to modern pharmacology. In 1938–1940, American chemist Russell Earl Marker developed the process known as Marker degradation, which converts diosgenin from Mexican Dioscorea yams into 16-dehydropregnenolone acetate, which has a four-ring structure and can be used to synthesize commonly used steroid hormones.

The surprising hub was Mexico City, where Syntex converted diosgenin, a sapogenin from Mexican yams, into a versatile steroid precursor and used it to develop a landmark process for the synthesis of cortisone and progestins — a chemical platform that enabled the first oral contraceptive and helped to make steroid-based pharmaceuticals more available.

Diosgenin serves primarily as a crucial precursor in the industrial synthesis of pharmaceutically important steroid hormones, including progesterone, cortisone, pregnenolone, and testosterone, through processes like the Marker degradation. Most of the therapeutically useful steroidal drugs, including sex hormones and corticosteroids, are produced in a semisynthetic fashion from natural precursors and predominantly from diosgenin.

Even today, the Marker Degradation process of synthesizing progesterone from the Mexican yam's diosgenin is utilized for the production of progesterone for medical applications.

7. Dosage Forms and Reported Dosages

Dosage information for 25-D-spirosta-3,5-diene as an isolated compound is not available in the peer-reviewed literature. The following dosages are those reported in studies of the parent compound diosgenin and botanical Dioscorea preparations:

• Animal study (diabetic neuropathy model): In a mouse study evaluating neuroprotective effects, eligible mice received low-dose (50 mg/kg) or high-dose (100 mg/kg) diosgenin administered over 8 weeks following dietary and pharmacological induction of diabetes.
• Animal study (ovariectomized model): Research by Aradhana and colleagues in 1992 demonstrated that administration of diosgenin at doses of 20 or 40 mg/kg for a period of 15 days significantly stimulates the growth of the mammary epithelium in an ovariectomized animal model.
• Topical preparations: Topical D. villosa with an upper limit of 3.5% diosgenin was not found to be systemically toxic or genotoxic in safety evaluations.
• Oral DHEA (related compound, human): No adverse effects were reported in postmenopausal women using DHEA for 52 weeks at the dosage of 50 mg daily.

No verified human clinical dosages for diosgenin or 25-D-spirosta-3,5-diene administered as isolated oral supplements have been confirmed in the sources reviewed for this article.

8. Bioavailability

Diosgenin is known to have poor aqueous solubility and undergoes rapid metabolic degradation, which hinders its bioavailability.

Several studies have reported poor bioavailability of diosgenin due to its strong hydrophobic nature and low aqueous solubility. Further, this compound, being a substrate for P-glycoprotein, exhibits poor intestinal permeability and bioavailability. Pharmacokinetic studies have revealed that the total bioavailability of diosgenin is only about 7% in rats.

Poor pharmacokinetic profile, low bioavailability, low aqueous solubility, and instability in the gastrointestinal tract limit the clinical application of diosgenin and its analogs. More information on the pharmacokinetics and metabolism is required, and it is necessary to develop more efficient drug delivery systems and safer and more effective derivatives to improve bioavailability.

Detailed ADME (absorption, distribution, metabolism, and excretion) studies are urgently required to characterize the pharmacokinetic profile adequately. Emerging research has explored nanotechnological delivery systems — including liposomes and polymeric nanoparticles — to address this limitation.

9. Safety Considerations

9.1 General Toxicological Profile

Natural steroidal saponins usually have high safety profiles. Preclinical studies showed mild subchronic toxicity in male rats but not in female rats treated with diosgenin.

Daily administration of diosgenin above 300 mg/kg may cause mild gastrointestinal distension, hemolytic anemia, and weight loss in rats; while long-term use of steroidal saponins in large doses has been reported to damage the liver, leading to conditions such as acute icteric hepatitis. However, at moderate doses, diosgenin showed a significant protective effect on liver injury induced by ethanol and paracetamol. The oral toxicity dosage (LD₅₀) of diosgenin to mice and rats has been reported as greater than 8,000 mg/kg (greater than 480 g per human equivalent). Therefore, diosgenin and its analogs are considered safe and non-toxic at conventional dosage, though the safety of other analogs needs further exploration.

9.2 In Vitro Cytotoxicity Data

In cultured hepatocytes and V79 fibroblasts, cytotoxic effects of spirostane derivatives were examined; derivatives were obtained by modifying the A and B rings of diosgenin. Diosgenin and its derivatives were more toxic in V79 fibroblasts (IC₅₀ 40–300 µM) than in hepatocytes (IC₅₀ 280–1000 µM). These in vitro findings at high concentrations do not necessarily predict in vivo toxicity but indicate concentration-dependent cell-level effects.

9.3 Sex-Differential Toxicity

Mild subchronic toxicity was observed in male rats but not in female rats treated with diosgenin in preclinical studies, suggesting a possible sex-differential response that warrants further investigation.

9.4 Renal Considerations

D. villosa should be avoided in people with compromised renal function.

9.5 Safety of Topical Forms

Dioscorea villosa root extract has been assessed as safe as used in cosmetic formulations; this conclusion regarding safety, however, is valid only for extracts prepared in a manner that produces a similar chemical profile as described in the relevant safety report, particularly as regards diosgenin content.

9.6 Clinical Safety Signal

Clinical investigations have demonstrated diosgenin's nontoxic nature and promising benefits on cognitive function and menopause; however, further well-designed clinical trials are needed to address the other effects seen in preclinical studies, as well as a better knowledge of the diosgenin's safety profile.

9.7 Limitations of Safety Evidence

Further well-designed clinical trials are needed to address the other effects seen in preclinical studies, as well as a better knowledge of the diosgenin's safety profile. No specific safety data are available for 25-D-spirosta-3,5-diene as an isolated administered compound in humans. Since this compound may be formed as a processing artifact during saponin hydrolysis, its proportion in any given extract is variable and typically not disclosed in finished product testing.

10. Body Systems and Health Areas of Association

Based on the peer-reviewed literature for diosgenin and the spirostane sapogenin class, the body systems with documented preclinical associations include:

• Oncology: Multiple cancer cell lines; apoptosis, anti-proliferation, anti-metastasis
• Cardiovascular system: Cholesterol metabolism, anti-atherosclerosis, lipid peroxidation reduction
• Endocrine/Metabolic: Blood glucose regulation, adipogenesis (via PPARγ), lipid homeostasis
• Nervous system: Neuroprotection, neuroinflammation suppression, Alzheimer's and Parkinson's disease models, diabetic peripheral neuropathy
• Musculoskeletal: Bone mineral density, osteoarthritis chondrocyte protection (via JAK2/STAT3 and SIRT1 pathways)
• Reproductive/Hormonal: Estrogenic activity in experimental models (not via direct receptor binding confirmed in vivo); mammary epithelial stimulation in animals
• Immune system: Immunomodulation, T-cell regulation, macrophage function
• Respiratory: Anti-tracheal inflammation, anti-asthmatic effects in animal models
• Skin: Anti-photoaging, anti-inflammatory effects in skin models
• Thyroid: Anti-goitrogenic effects in Graves' disease mouse models

11. Current Research Gaps and Translational Status

There is a necessity for pilot human studies, beginning with Phase 0 or early bioavailability trials in healthy volunteers to characterize absorption, tolerability, and pharmacokinetics of both free and nanoformulated diosgenin.

The fundamental challenge for 25-D-spirosta-3,5-diene specifically is that, unlike diosgenin, it has not been independently isolated and tested in rigorous pharmacological assays. It appears in botanical extracts as a minor component whose formation is at least partly an artifact of processing. Evidence suggests that the diene is actually an artifact derived from diosgenin and produced early during the acid hydrolysis of the natural saponins. This means that any therapeutic claim specifically attributed to 25-D-spirosta-3,5-diene — as distinct from the broader sapogenin fraction — is not supported by the available peer-reviewed evidence.

There is little modern clinical research on Dioscorea villosa, and the one study of a wild yam-containing cream for menopausal symptoms failed to find any value.

Studies on diosgenin and its analogs in atherosclerosis and their effect on immune regulation are still lacking, while studies reporting on other analogs are just in the infancy stage.

References

• (25R)-Spirosta-3,5-diene | CID 337494 — PubChem, NIH
• Diosgenin — NIST WebBook, National Institute of Standards and Technology
• Bedour et al. (1964). "Steroid sapogenins VII. Identification and origin of 25D-spirosta-3,5-diene among the fenugreek sapogenins." Journal of Pharmaceutical Sciences
• Semwal et al. (2022). "Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives." Oxidative Medicine and Cellular Longevity — PMC9168095
• Ramos et al. (2017). "Diosgenin: Recent Highlights on Pharmacology and Analytical Methodology." Journal of Analytical Methods in Chemistry — PMC5225340
• Chen Y. et al. (2015). "Advances in the pharmacological activities and mechanisms of diosgenin." Chinese Journal of Natural Medicines — PubMed 26253490
• Jiang et al. (2022). "Diosgenin and its analogs: Potential protective agents against atherosclerosis." Drug Design, Development and Therapy — Dove Medical Press
• Dong et al. (2016). "Antiproliferative and anti-inflammatory polyhydroxylated spirostanol saponins from Tupistra chinensis." PMC4987684
• Wang et al. (2022). "Diosgenin From Dioscorea Nipponica Rhizoma Against Graves' Disease — On Network Pharmacology and Experimental Evaluation." PMC8819592
• Ohashi et al. (2021). "Diosgenin Prevents Microglial Activation and Protects Dopaminergic Neurons from LPS-Induced Neural Damage In Vitro and In Vivo." PMC8508726
• Li et al. (2020). "Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway." PMC7184706
• Zhang et al. (2018). "An update on the biological and pharmacological activities of diosgenin." PMC5780621
• Nikolic et al. (2012). "Diarylheptanoids from Dioscorea villosa (Wild Yam)." PMC3710746
• Diosgenin — ScienceDirect Topics overview
• Ansari et al. (2026). "Therapeutic potential of diosgenin in hepatocellular carcinoma through molecular mechanisms and nanodelivery strategies." Discover Oncology — Springer
• Rizwan ur-Rehman et al. (2024). "Diosgenin: A Potential Therapeutic Phytocompound for the Management of Atherosclerosis and Other Physiological Disorders." Natural Product Communications
• Marker degradation — Wikipedia (sourced to primary literature)
• Sneader et al. (2025). "The origins of oral contraception: The role of Mexican scientists in developing the first synthetic oral contraceptive progestin." Steroids — ScienceDirect
• Wild Yam: Uses, Benefits & Dosage — Drugs.com Natural Products Database
• Hernández-Linares et al. (2012). "Diosgenin hemihydrate." Acta Crystallographica Section E — PMC